Searched for
SPINAL MUSCULAR ATROPHY
Scientists thought the human brain began as one: New study reveals two ancient cell pathways emerge early, raising a surprising question about how our most complex organ formsScientists have uncovered a surprising twist in human brain development: two distinct groups of early cells follow separate paths to form d...- In 2000, Johns Hopkins team treated 18 paralyzed rodents with neural stem cells. 6 years later, the team engineered working motor-neuron circuits in paralyzed adult animals, extending the original findingJohns Hopkins research from 2000 and 2006 represents an important scientific progression in the search for ways to repair damaged nervous s...
- US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, the company said on M...
- US FDA approves Novartis' gene therapy for rare muscle disorderThe US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma...
- Roche moves SC against Natco’s launch of generic Risdiplam in IndiaF. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a g...
- More patients can access key drugs after GST rate cutsRecent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...
- Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itselfA recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SM...
- Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent disputeThe Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...
- Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patentThe Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...
- SC stays order asking Centre to procure drugs for patient with rare disorderThe Supreme Court has temporarily stayed a Kerala High Court order directing the Centre to provide additional funds for a patient's expensi...
- Spinal Muscular Atrophy: Indira Gandhi Institute to offer free treatment for childrenKarnataka launched free treatment for Spinal Muscular Atrophy (SMA) at the Indira Gandhi Institute of Child Health in Bengaluru. The initia...
- Rs 17 crore for a single dose: Why Zolgensma is world's most expensive medicineThe high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patien...
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert"The focus will be on prevention rather than cure. In this, citizens are diagnosed technically to see what diseases they could be afflicted...
- COVID-19: Mumbai gets its first genome sequencing labThe lab was inaugurated virtually by Maharashtra Chief Minister Uddhav Thackeray. Another project- Spinraza therapy for spinal muscular atr...
- Roche launches spinal muscular atrophy treatment drug in India priced at around Rs 6 lakh per bottleSince its launch, over 4,000 SMA patients across over 50 countries have benefitted from the drug, Roche said in a statement.
- Scrap taxes on drug import for spinal muscular atrophy, Stalin tells CentreFor children affected by SPA, gene-therapy has to be ideally given before the child reaches two years of age and this therapy costs over Rs...
- Don't want Tom, Dick and Harry to collect money: HC on crowdfunding for treatment of rare diseasesJustice P B Suresh Kumar said the court does not want to interdict the crowdfunding process, but it wants the funds to go to the government...
- Donation call: Rs 4 crore in 1 week can save Ayaansh7 days left to save Ayaansh with 4 crore: Donate on ImpactGuru.
- India notifies first policy on rare diseasesIn the new policy, formulated after detailed stakeholder consultations, 'rare diseases' have not been defined but classified into three gro...
- Drug for spinal muscular atrophy disease already exempt from import duty: FMGiving a clarification on the issue raised by Congress Vivek K Tankha during Zero Hour on March 17, Sitharaman in Rajya Sabha said the memb...
Load More
